Wanted pages

From Glioblastoma Treatments
Jump to navigationJump to search

List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.

Showing below up to 50 results in range #301 to #350.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Preclinical studies and early human trials for cancer‏‎ (1 link)
  2. Preclinical studies and early research‏‎ (1 link)
  3. Preclinical studies and observational studies in animals and humans‏‎ (1 link)
  4. Preclinical studies and some clinical trials‏‎ (1 link)
  5. Preliminary data suggest potential improvement in overall survival, but specific figures for GBM are under investigation‏‎ (1 link)
  6. Preliminary data suggest potential improvement in progression-free survival, but specific figures for GBM are under investigation‏‎ (1 link)
  7. Primary GBM: median survival of 5.9 months; Secondary GBM: median survival of 11.2 months‏‎ (1 link)
  8. Progression-free survival of 6-12 months reported in some studies‏‎ (1 link)
  9. Prospective study shows median PFS of 10.5 months‏‎ (1 link)
  10. Radiation‏‎ (1 link)
  11. Reported side effects are minimal, including potential site reactions and flu-like symptoms. Few serious adverse events related to the vaccine have been reported.‏‎ (1 link)
  12. Research ongoing‏‎ (1 link)
  13. Resveratrol is being studied for its potential anti-cancer properties in preclinical and early clinical trials, focusing on its ability to modulate various signaling pathways involved in cell proliferation and survival.‏‎ (1 link)
  14. Retrospective Studies‏‎ (1 link)
  15. Retrospective studies and a prospective phase II trial‏‎ (1 link)
  16. Retrospective studies and laboratory research‏‎ (1 link)
  17. Reviewed in recent meta-analyses and studies‏‎ (1 link)
  18. Sativex combined with dose-intense temozolomide: Median survival exceeded 550 days (over 18 months)‏‎ (1 link)
  19. Shows potential for treating recurrent GBM, especially in specific genetic profiles like unmethylated MGMT promoter. Comparative mOS suggests potential improvement over lomustine.‏‎ (1 link)
  20. Shows promise for targeted radiation delivery to tumor cells with potential for sparing normal tissue and reducing side effects, but more research is needed for a definitive assessment‏‎ (1 link)
  21. Significant in the context of preliminary findings from retrospective studies‏‎ (1 link)
  22. Significant reduction in tumor size noted, durability of response under investigation‏‎ (1 link)
  23. Silibinin (Silymarin)‏‎ (1 link)
  24. Specifics depend on individual drugs; can include rash, diarrhea, and potential infusion reactions‏‎ (1 link)
  25. Standard progression statistics for GBM‏‎ (1 link)
  26. Standard progression statistics for GBM.‏‎ (1 link)
  27. Standard treatment: median survival of 16.1 months‏‎ (1 link)
  28. Studies suggest PPIs may improve progression-free survival in cancer treatment‏‎ (1 link)
  29. Studies suggest a potential improvement in overall survival, with some reports indicating up to 20-24 months in certain patient populations‏‎ (1 link)
  30. Studies suggest improved survival rates in various cancers when added to chemotherapy; specific glioma-related outcomes are less clear‏‎ (1 link)
  31. Study-specific; one phase 2 trial reported no significant difference in PFS with the addition of celecoxib‏‎ (1 link)
  32. The combination of CPT-11 with agents like Bevacizumab and Temozolomide has shown potential in treating recurrent malignant gliomas, suggesting a meaningful clinical benefit in this challenging patient population.‏‎ (1 link)
  33. The primary advantage of GKRS for GBM lies in its lower toxicity profile, offering a safer treatment option for select patients without compromising on the progression-free survival (PFS) or overall survival (OS) rates.‏‎ (1 link)
  34. Tiredness, diarrhea, changes in appetite/weight; generally well-tolerated at doses used for epilepsy‏‎ (1 link)
  35. Transient, low-grade local reactions; overall well-tolerated‏‎ (1 link)
  36. Typically less than 7 months for newly diagnosed GBM under standard treatment‏‎ (1 link)
  37. Under investigation; initial results indicate possible benefits in slowing disease progression‏‎ (1 link)
  38. Under investigation; shown to have anti-cancer effects in laboratory studies‏‎ (1 link)
  39. Under investigation; some studies suggest potential for improved outcomes in cancer patients on metformin‏‎ (1 link)
  40. Used in various studies for cancer treatment‏‎ (1 link)
  41. Valproic acid users: retrospective study shows median survival of 16.9 months, prospective study shows 29.6 months‏‎ (1 link)
  42. Variable across studies; for example, a study combining Temodar with Celebrex showed a PFS-6 of 35%, another combining Celebrex with CPT-11 showed PFS-6 of 25%‏‎ (1 link)
  43. Varied, with multiple studies evaluating efficacy and optimal scheduling‏‎ (1 link)
  44. Varied; includes studies with mixed outcomes‏‎ (1 link)
  45. Varies; cannabis is known for minimal side effects such as dry mouth, red eyes, and increased appetite. Sativex may have additional side effects similar to other cannabis products.‏‎ (1 link)
  46. Varies; for leukemia treatment includes fluid retention, nausea, muscle cramps, rashes, and fatigue. Brain tumor studies may have different profiles due to combination treatments and patient population.‏‎ (1 link)
  47. Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis‏‎ (1 link)
  48. Varies; one combination showed median survival of 20 months, another study reported median survival up to 29.6 months with high-dose Valproic Acid‏‎ (1 link)
  49. Varies based on the combination; potential for increased chemotherapy toxicity‏‎ (1 link)
  50. Varies by specific ARB; can include dizziness, hypotension, and renal function alteration‏‎ (1 link)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Special:WantedPages"